Uploaded January 2023 | Updated November 2026, 16 minutes ago
Novartis is transforming into a ‘pure-play’ Innovative Medicines company.
In this video, Shreeram Aradhye, President, Global Drug Development & Chief Medical Officer at Novartis discusses how Novartis is focusing on high priority programs, clear regulatory strategies, and relentless operational discipline. These are central to our drug development and pipeline approach as we transform Novartis into a ‘pure play’ Innovative Medicines company.
Meet Novartis Management
Event Date: September 22, 2022
Investors Page: bit.ly/3HjEp1q
Link to Novartis Strategy: bit.ly/3QRnRAU
Disclaimer: Meet Novartis Management event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: bit.ly/3Wrsq6n
Follow @Novartis on Twitter: twitter.com/Novartis
Follow Novartis on LinkedIn: linkedin.com/company/novartis
Novartis is transforming into a ‘pure-play’ Innovative Medicines company.
In this video, Shreeram Aradhye, President, Global Drug Development & Chief Medical Officer at Novartis discusses how Novartis is focusing on high priority programs, clear regulatory strategies, and relentless operational discipline. These are central to our drug development and pipeline approach as we transform Novartis into a ‘pure play’ Innovative Medicines company.
Meet Novartis Management
Event Date: September 22, 2022
Investors Page: bit.ly/3HjEp1q
Link to Novartis Strategy: bit.ly/3QRnRAU
Disclaimer: Meet Novartis Management event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: bit.ly/3Wrsq6n
Follow @Novartis on Twitter: twitter.com/Novartis
Follow Novartis on LinkedIn: linkedin.com/company/novartis

